The Challenges of Treating Paraganglioma Patients with (177)Lu-DOTATATE PRRT: Catecholamine Crises, Tumor Lysis Syndrome and the Need for Modification of Treatment Protocols

about

The Challenges of Treating Paraganglioma Patients with (177)Lu-DOTATATE PRRT: Catecholamine Crises, Tumor Lysis Syndrome and the Need for Modification of Treatment Protocols

Item

http://www.wikidata.org/entity/Q35941125

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

The Challenges of Treating Par ...... ication of Treatment Protocols

@ast

The Challenges of Treating Par ...... ication of Treatment Protocols

@en

type

Item

label

The Challenges of Treating Par ...... ication of Treatment Protocols

@ast

The Challenges of Treating Par ...... ication of Treatment Protocols

@en

prefLabel

The Challenges of Treating Par ...... ication of Treatment Protocols

@ast

The Challenges of Treating Par ...... ication of Treatment Protocols

@en

P1476

The Challenges of Treating Par ...... ication of Treatment Protocols

@en

P2093

Alexander J B McEwan

http://www.w3.org/2001/XMLSchema#string

Karey McCann

http://www.w3.org/2001/XMLSchema#string

William Makis

http://www.w3.org/2001/XMLSchema#string

P2860

177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide.

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.

Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome.

Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma.

Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005.

Pheochromocytoma crisis induced by glucocorticoids: a report of four cases and review of the literature.

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate.

An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome.

Multiple actions of somatostatin in neoplastic disease.

P2888

s13139-015-0332-6

P304

223-230

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13139-015-0332-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275241675

http://www.w3.org/2001/XMLSchema#string

P698

26279696

http://www.w3.org/2001/XMLSchema#string

P932

4532685

http://www.w3.org/2001/XMLSchema#string